Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has received a consensus rating of “Buy” from the nine analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $26.14.
SYRS has been the subject of a number of research reports. Zacks Investment Research lowered shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. ValuEngine lowered shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 22nd. Cann restated a “buy” rating and issued a $28.00 price objective on shares of Syros Pharmaceuticals in a research report on Monday, August 21st. Roth Capital began coverage on shares of Syros Pharmaceuticals in a research report on Monday, October 23rd. They issued a “neutral” rating and a $15.00 price objective for the company. Finally, Piper Jaffray Companies restated an “overweight” rating and issued a $30.00 price objective on shares of Syros Pharmaceuticals in a research report on Tuesday, October 31st.
Shares of Syros Pharmaceuticals (NASDAQ:SYRS) traded up $0.53 during trading hours on Friday, reaching $13.30. 209,300 shares of the company’s stock were exchanged, compared to its average volume of 92,097. Syros Pharmaceuticals has a 12-month low of $10.22 and a 12-month high of $24.38.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Wednesday, November 8th. The company reported ($0.53) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.53). sell-side analysts expect that Syros Pharmaceuticals will post -2.09 EPS for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the company. Nationwide Fund Advisors boosted its position in shares of Syros Pharmaceuticals by 249.8% in the second quarter. Nationwide Fund Advisors now owns 7,024 shares of the company’s stock valued at $113,000 after acquiring an additional 5,016 shares during the period. Russell Investments Group Ltd. bought a new position in shares of Syros Pharmaceuticals in the third quarter valued at approximately $133,000. Cubist Systematic Strategies LLC bought a new stake in Syros Pharmaceuticals during the third quarter valued at approximately $149,000. The Manufacturers Life Insurance Company lifted its position in Syros Pharmaceuticals by 11,253.8% during the second quarter. The Manufacturers Life Insurance Company now owns 10,559 shares of the company’s stock valued at $170,000 after purchasing an additional 10,466 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Syros Pharmaceuticals during the first quarter valued at approximately $185,000. Institutional investors own 55.19% of the company’s stock.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.